Liquidia Technologies Inc (LQDA) — Technical state
As of 2026-11-02 — re-computed nightly across the coverage universe. Closelooknet diary readings, not advice.
The Closelooknet read
- Closelooknet score: 47 out of 100 (momentum 31 · quality 68 · valuation 31), as of 2026-11-03.
- Signal: Mixed moving-average stack — Trades -20.2% vs the 50-day and -22.9% vs the 200-day average, 55.3% below the 52-week high and +88.5% off the 52-week low; a death cross printed 4 sessions ago. Computed from daily closes. (as of 2026-11-02)
- Trend: Liquidia Technologies Inc trades 20.2% below its 50-day and 22.9% below its 200-day moving average. (as of 2026-11-02)
Liquidia Technologies develops and sells therapies for rare heart-and-lung diseases, mainly pulmonary hypertension. Its lead product, Yutrepia, is an inhaled dry-powder form of treprostinil, and it also sells Remodulin, an injected version of the same drug given through a pump.
The full read — the desk's view, the earnings record, peers and the company snapshot — is on the LQDA overview. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.
Trades -20.2% vs the 50-day and -22.9% vs the 200-day average, 55.3% below the 52-week high and +88.5% off the 52-week low; a death cross printed 4 sessions ago. Computed from daily closes.
Ranked #8 on today’s Directional Flow — Falling fastest list (scan of 2026-11-02).
The moving-average stack
- vs 20-day+15.6%
- vs 50-day-20.2%
- vs 200-day-22.9%
- 52-week band55.3% off the high · +88.5% off the low
- Streak1 consecutive down session
- CrossoverDeath cross 4 sessions ago
- 50-day crossprice crossed down through the 50-day 56 sessions ago
- Stochastic%K 64.3 · %D 90.8
Continue: the LQDA chart & overview · quality & forensics · the earnings record · the signal board
FAQ · from the current data · as of 2026-11-02
Quick answers
What is the current Closelooknet signal on LQDA?
Mixed moving-average stack — Trades -20.2% vs the 50-day and -22.9% vs the 200-day average, 55.3% below the 52-week high and +88.5% off the 52-week low; a death cross printed 4 sessions ago. Computed from daily closes. As of 2026-11-02; the signal board re-computes across the coverage universe nightly. A research diary reading, not advice.
Is LQDA above its 50-day and 200-day moving averages?
As of 2026-11-02, Liquidia Technologies Inc trades -20.2% below its 50-day and -22.9% below its 200-day average, with the 20-day +15.6% away.
How far is LQDA from its 52-week high?
55.3% below the 52-week high and 88.5% above the 52-week low, as of 2026-11-02.
Related in the Closelooknet universe
then Drug Manufacturers - Specialty & Generic. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- ROVI.MC Laboratorios Farmaceuticos ROVIindustry
- LNTH Lantheus Holdings Incindustry
- GALDY GALDERMA GROUP AGindustry
- KNSA Kiniksa Pharmaceuticals Ltdindustry
- ALM.MC Almirall S.A.industry
- IRWD Ironwood Pharmaceuticals Incindustry
- BHC.TO Bausch Health Companies Incindustry
- PCRX Pacira BioSciences, Inc.industry
- HLUN-B.CO H Lundbeck A/Sindustry
- UTHR United Therapeutics Corporationindustry
- VETO.PA Vetoquinolindustry
- XERS Xeris Pharmaceuticals Incindustry
- AMPH Amphastar Pindustry
- GUD.TO Knight Therapeutics Inc.industry
- VTRS Viatris Incindustry
- 000538.SHE Yunnan Baiyao Group Co Ltdindustry
- PRGO Perrigo Company PLCindustry
- ELAN Elanco Animal Healthindustry
- FAE.MC Faes Farma SAindustry
- INDV Indivior PLC Ordinary Sharesindustry